<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842217</url>
  </required_header>
  <id_info>
    <org_study_id>NL41 608.042.12</org_study_id>
    <nct_id>NCT01842217</nct_id>
  </id_info>
  <brief_title>Validation of [18F]FES for Imaging of Brain Estrogen Receptors</brief_title>
  <official_title>Validation of [18F]FES for Imaging of Brain Estrogen Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.W.J.M.Glaudemans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Validation of [18F]-FES for imaging of estrogen receptors in the brain&#xD;
&#xD;
      The primary objective of the study is to determine if [18F]-FES Positron Emission Tomography&#xD;
      (PET) can be used to quantify the estrogen receptor expression in the human brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estrogens are the primary female sex hormones that play a major role in the development and&#xD;
      maintenance of secondary sexual functions. In addition, estrogens play an important role in&#xD;
      cardiovascular, musculoskeletal, immunological, bone development and central nervous system&#xD;
      processes. Actions of estrogens are mediated by a group of specialized receptors, known as&#xD;
      estrogen receptors. Estrogens were found to be neuroprotective and may thus protect against&#xD;
      development of neurodegenerative disorders like Alzheimer's disease, Parkinson's disease and&#xD;
      multiple sclerosis. In addition, estrogens may also play an important role in psychiatric&#xD;
      disorders, like depression. To improve our understanding of the action of estrogens in the&#xD;
      brain, it is important to study the expression of estrogen receptors in the brain. Positron&#xD;
      emission tomography (PET) is the most suitable technique for non-invasive imaging of brain&#xD;
      receptors. [18F]FES is a PET tracer that is regularly used in the UMCG to image the estrogen&#xD;
      receptor expression in breast cancer patients, but has never been used for quantitative&#xD;
      imaging of brain estrogen receptors. Quantification of the expression of brain receptors by&#xD;
      PET usually requires arterial blood sampling to obtain the plasma input function of the&#xD;
      tracer. Arterial blood sampling causes discomfort to the patient and therefore can be an&#xD;
      obstacle especially in longitudinal studies. The aim of this study is therefore to&#xD;
      investigate whether [18F]FES PET imaging for quantification of estrogen receptors in the&#xD;
      human brain is feasible without arterial blood sampling, using a reference tissue model&#xD;
      (SRTM) or an image derived input function (IDIF), so the discomfort associated with arterial&#xD;
      blood sampling can be avoided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of estrogen receptors in the human brain</measure>
    <time_frame>1 year</time_frame>
    <description>The primary objective of the study is to validate the use of a reference tissue model and an image derived input function for the quantification of ERs in the human brain, by [18F]FES PET, using pharmacokinetic modelling with arterial sampling as golden standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evalution of the levels of circulating estradiol in two patient cohorts and to evaluate the imaging technique</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the effect of the levels of circulating estradiol on quantification of ERs in the human brain, by comparing premenopausal women with postmenopausal women.&#xD;
To investigate whether PET acquisition time can be shortened to reduce the subjects discomfort, as the current protocol requires the patient to be scanned for 90 min.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Psychiatric/Mood Disorder | Patient</condition>
  <condition>Estrogen Receptor Levels</condition>
  <condition>Premenopausal</condition>
  <condition>Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Premenopausal women</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy female subjects: premenopausal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postmenopausal women</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy female subjects: postmenopausal</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FES-PET</intervention_name>
    <arm_group_label>Postmenopausal women</arm_group_label>
    <arm_group_label>Premenopausal women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  For postmenopausal women: at least 1 year after menopause&#xD;
&#xD;
          -  For premenopausal women: a regular menstruation&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of estrogen receptor ligands, such as tamoxifen or fulvestrant&#xD;
&#xD;
          -  History of ER-positive malignancies or breast cancer&#xD;
&#xD;
          -  Use of any contraceptive drugs (pill, injections or implanted)&#xD;
&#xD;
          -  For postmenopausal women: (history of) estrogen replacement therapy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of removal of the ovaries and/or the uterus&#xD;
&#xD;
          -  Current systemic diseases&#xD;
&#xD;
          -  Major metabolic diseases (e.g. diabetes, hyper- or hypothyroidism)&#xD;
&#xD;
          -  Somatic, organic or neurological disorders&#xD;
&#xD;
          -  Recent participation in a scientific research study (&lt;1 year) involving radiation&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Presence of materials in the body that can be magnetized, like: pacemaker, metallic&#xD;
             implants/prostheses, metal fragments, shunts, artificial heart valves, vascular clips,&#xD;
             fixed hearing aid, tattoos containing metal, hair implants, artificial dentures&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andor Glaudemans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Khayum, MSc</last_name>
    <phone>0031503613375</phone>
    <email>m.a.khayum@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janine Doorduin, PhD</last_name>
    <phone>0031503610151</phone>
    <email>j.doorduin@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Khayum, MSc</last_name>
      <phone>0031503613375</phone>
      <email>m.a.khayum@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Janine Doorduin, PhD</last_name>
      <phone>0031503610151</phone>
      <email>j.doorduin@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Andor Glaudemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>April 24, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>November 11, 2013</last_update_submitted>
  <last_update_submitted_qc>November 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.W.J.M.Glaudemans</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>18F-FES PET</keyword>
  <keyword>Nuclear Medicine</keyword>
  <keyword>Premenopausal</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Estrogen receptor</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Depression</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

